Caris Life Sciences Reports 94% Revenue Growth for 2025
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 12 2026
0mins
Source: PRnewswire
- Significant Revenue Growth: Caris Life Sciences reported approximately 94% revenue growth for 2025, driven by strong performance in molecular profiling services, indicating sustained market demand in the precision medicine sector.
- Robust Cash Position: As of December 31, 2025, Caris had approximately $802 million in cash, cash equivalents, restricted cash, and marketable securities, reflecting a net increase of about $43 million from September 30, 2025, enhancing the company's financial flexibility.
- Enhanced Market Positioning: The successful public listing in 2025 marked a breakthrough for Caris, showcasing the scale and impact of its molecular profiling platform and further solidifying its leadership in the precision medicine industry.
- Positive Future Outlook: The company plans to report complete financial results during its earnings call in late February 2026, which is expected to further drive clinical adoption and the development of a differentiated product pipeline.
Analyst Views on CAI
Wall Street analysts forecast CAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for CAI is 37.60 USD with a low forecast of 30.00 USD and a high forecast of 45.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
7 Analyst Rating
6 Buy
1 Hold
0 Sell
Strong Buy
Current: 25.480
Low
30.00
Averages
37.60
High
45.00
Current: 25.480
Low
30.00
Averages
37.60
High
45.00
About CAI
Caris Life Sciences Inc. is a patient-centric, next-generation artificial intelligence tech bio company and precision medicine provider. The Company develops and commercializes solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Its entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets. Its platform is purpose-built to leverage the convergence of next-generation sequencing (NGS), artificial intelligence (AI) and machine learning (ML) technologies, and high-performance computing. Its purpose-built, proprietary multi-omic profiling solutions capture and analyze molecular information from tissue and blood in a comprehensive manner. Its services for biopharma companies include prospective and retrospective profiling services, and companion diagnostics development.
About the author

Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.








